: Truelieve Cannabis Corp. new listing on CSE
News;: provided by Trulieve Cannabis Corp. /Sep 24, 2018https://www.a Zitat:"UINCY, FL, Sept. 24, 2018 /CNW/ - Trulieve Cannabis Corp. (CSE: TRUL) ("Trulieve" or the "Company") today announces its financial results for the three and six-month periods ended June 30, 2018. The Company's second quarter 2018 financial statements have been filed as part of its listing statement with the Canadian Securities Exchange ("CSE"). This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.
Unless otherwise stated, all currency is expressed in U.S. dollars. /Q2 2018 Highlights: 16 dispensaries in operation 83,000 active unique patients Revenue grew from $15.2 million in Q1 2018 to $23.3 million in Q2 2018. EBITDA1 increased from $11.2 million in Q1 2018 to $14.3 million in Q2 2018
"The second quarter of 2018 demonstrated our ability to scale our business profitably with growth in dispensaries and patients served driving growth in revenue and EBITDA1," said Kim Rivers, CEO of Trulieve. "This momentum is continuing in the current quarter and we expect strong results throughout 2018." " ENDE Zitat QUelle:https://www.newswire.ca/news-releases/trulieve-achieves-significant-growth-in-the-second-quarter-of-2018-694106281.html
Zitat:" C.TRUL | 1 day ago Vancouver, British Columbia--(Newsfile Corp. - September 27, 2018) - Trulieve Cannabis Corp. (CSE: TRUL) is the latest new listing on the Canadian Securities Exchange, following a RTO with Schyan Exploration Inc., a reporting issuer in the Province of Ontario. Trulieve US is the first and largest fully-licensed medical cannabis company in the state of Florida and serves over 80,000 patients...." ENDE Zitat Quelle:http://www.stockhouse.com/news/press-releases/2018/09/27/cse-new-listing-trulieve-cannabis-corp-commences-trading-on-the-canadian
: Coverage with "buy" rating... 22.01.2019
Zitat:".. Beacon Securities analyst Russell Stanley commenced coverage on Trulieve Cannabis ($13.64) with a "buy" rating. The Globe's David Leeder writes that Mr. Stanley says in a note: "Trulieve dominates the Florida cannabis market. ... This is a highly concentrated medical cannabis market. ... Its Q3/18 EBITDA margins of 44 per cent are otherwise unheard of amongst publicly traded cannabis companies. ... The company has also made significant progress in expanding to California and Massachusetts, which should support continued revenue/EBITDA expansion." He set a Street-high share target of $28, $3... " ENDE Zitat Quelle/: https://www.stockwatch.com/News/...09068&symbol=TRUL®ion=C https://www.stockwatch.com/Chart/...me=1&symbol=TRUL®ion=C